Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.

Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis D virus (HDV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HDV infection and/or HDV-associated disorder.

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis B virus (HBV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection and/or HBV-associated disorder, e.g., chronic hepatitis B infection.

Abstract: A fuel distributor, which is used, in particular, for fuel injection systems of mixture-compressing, internal combustion engines having externally supplied ignition, includes a distributor pipe, a first holder and at least one second holder. The distributor pipe has a longitudinal axis. In this connection, the first holder and the second holder are situated at the distributor pipe so as to be axially set apart from one another with respect to the longitudinal axis. The distributor pipe is designed to allow axial length compensation. It is also possible for at least one holder to be designed to allow axial length compensation.

Abstract: The present invention provides an inhalable formulation comprising a ligand conjugated oligonucleotide and particles of a physiologically acceptable pharmacologically-inert carrier.

Abstract: One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene. The dsRNA duplex comprises one or more motifs of three identical modifications on three consecutive nucleotides in one or both strand, particularly at or near the cleavage site of the strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.

Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.

Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2?-OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.

Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.

Abstract: A method for testing a high-pressure pump, particularly a high-pressure pump which is provided to inject fuel into a combustion engine, the method including filling the high-pressure pump with a fluid prior to switching it on.

Abstract: The description relates to a powder-metallurgical method for manufacturing components of a swivel motor for a vehicle steering system, said method involving the steps of: pressing 2, 3, 4, 5, 6 or any number of wing elements, assembling the wing elements, and sintering the assembled wing elements, and/or pressing 2, 3, 4, 5, 6 or any number of housing elements, assembling the housing elements, and sintering the housing elements.

Abstract: The present invention relates to lipid nanoparticles containing a biodegradable cationic lipid which provide improved delivery of active pharmaceutical ingredients, such as siRNA.

Abstract: A valve for controlling a fluid flow comprising: an inner sleeve having a control surface and a middle sleeve, wherein a first movement of the inner sleeve with respect to the middle sleeve can be carried out, wherein the valve comprises a control piston, wherein the first movement prompts a second movement of the control piston, whereby the valve is moved into a switched state.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC.

Abstract: An apparatus and a system for application of pressure to a fluid, as well as a corresponding use. The apparatus includes an introduction port for introducing the fluid into the apparatus; a cooling apparatus port and an outlet port; a controllable first valve device having an adjustable first opening pressure value; a second valve device having a second opening pressure value; a controllable third valve device having an adjustable third opening pressure value; the first valve device and the third valve device being automatically controllable for simultaneous application to the fluid of the first predefinable pressure value for output at the outlet port and of the second predefinable pressure value for output at the cooling apparatus port.

Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.

Abstract: A field bus module for the operation of actuators and/or sensors with at least one device interface for the connection of a sensor and/or actuator, with at least one field bus interface for connection to a field bus system, and with a processing device for receiving and processing and sending field bus telegrams and also for making available control commands, especially safety-oriented control commands, to the device interface depending on incoming field bus telegrams wherein the processing device is configured to process in different operating modes sensor data that can be made available at the device interface and/or field bus telegrams that can be made available at the field bus interface, wherein an operating mode memory is allocated to the processing device for the optional provision of one of at least two different operating mode data sets at the processing device depending on an incoming field bus telegram.